Partnerships and collaborations on vaccine development and evaluation

AI Summary

The Vaccine Development and Evaluation Centre (VDEC), a division of the UK Health Security Agency (UKHSA), serves as a strategic partner for the advancement, assessment, and delivery of vaccines and therapeutic products. Collaborating with industry, academia, and government, VDEC supports the lifecycle of medical products from initial assay development through clinical trials to final market licensure. Although the provided text describes VDEC's capabilities rather than an enforcement action, it highlights the organization's role within global regulatory and research frameworks. VDEC is an approved partner for the US Government’s Biomedical Advanced Research and Development Authority (BARDA) for animal model development and medical countermeasure testing. It also serves as an implementing partner for the Coalition of Epidemic Preparedness Innovations (CEPI) and is a member of the UK’s National Immunisation Schedule Evaluation Consortium (NISEC). Because this document is an overview of services and partnerships, there are no inspection dates, regulatory violations, or required corrective actions mentioned. The regulatory focus is on supporting pharmaceutical companies in meeting the necessary standards for clinical evaluation and product authorization. Organizations seeking to develop vaccines or antimicrobial treatments are invited to contact UKHSA to utilize VDEC’s expertise in high-containment modeling and clinical trial support.